Efficacy and safety of dual-targeted therapy in children with inflammatory bowel disease: Retrospective cohort study

Table 2 Characteristics of the study cohort

ID	Gender	Disease	Location of CD	Location of UC	Perianal disease	Extraintestinal involvement	Previous therapy	Current combination	Dose	Age of onset (years)	Age of beginning dual-targeted therapy (years)
1	M	CD	L3	-	No	No	5-ASA, GCS, AZA, INFL, UP	UP + VD	UP: 30 mg/day 12 weeks, then 15 mg/day. VD: 10 mg/kg/8 weeks	2	5
2	F	CD	L2	-	Yes	Yes	GCS, AZA, MTX, INFL, VD	VD + TOF/UP + UST	VD: 300 mg/6 weeks. TOF: 20 mg/day 8 weeks, then 10 mg/day. UP: 45 mg/day 12 weeks, then 30 mg/day. UST: 90 mg/4 weeks	11	12
3	M	UC	-	Pancolitis	-	Yes	5-ASA, GCS, AZA, MTX, INFL, ADA, VD	VD + TOF	VD: 300 mg/6 weeks. TOF: 20 mg/day 8 weeks, then 10 mg/day	7	10
4	M	UC	-	Pancolitis	-	No	5-ASA, GCS, AZA, INFL, UP	UP + VD	UP: 45 mg/day 8 weeks, then 30 mg/day. VD: 300 mg/8 weeks	11	13
5	M	CD	L3	-	Yes	No	5-ASA, GCS, AZA, MTX, INFL, ADA, TOF	TOF + VD	TOF: 20 mg/day 8 weeks, then 10 mg/day. VD: 300 mg/6 weeks	13	15
6	F	CD	L3+L4	-	No	No	Enteral nutrition, 5-ASA, GCS, TAC, SRL, INFL, ADA, VD, TOF	VD + UP	VD: 300 mg/6 weeks. UP: 45 mg/day 12 weeks, then 15 mg/day	2	12
7	M	UC	-	Left-sided	-	No	5-ASA, GCS, AZA, INFL, VD, TOF	TOF + ADA	TOF: 5 mg/day. ADA induction (40-80 mg), then 40 mg/2 weeks	2	2
8	M	CD	L2	-	Yes	Yes	GCS, AZA, TAC, INFL, ADA, UST	UST + UP	UST: 90 mg/4 weeks. UP: 45 mg/day 12 weeks, then 30 mg/day	8	15
9	F	UC	-	Pancolitis	-	Yes	5-ASA, GCS, AZA, INFL, VD	VD + UP	VD: 300 mg/6 weeks. UP: 45 mg/day 8 weeks, then 15 mg/day	6	13
10	F	UC	-	Left-sided	-	No	5-ASA, GCS, AZA, TAC, INFL, ADA	ADA + UP	ADA: 40 mg/2 weeks. UP: 30 mg/day 8 weeks, then 15 mg/day	2	6
11	M	CD	L3	-	No	No	GCS, AZA, INFL, ADA, UP	UP + UST	UP: 45 mg/day 12 weeks, then 30 mg/day. UST: 90 mg/8 weeks	14	16
12	M	CD	L2	-	No	Yes	GCS, AZA, MTX, INFL, VD, TOF	VD + UP	VD: 300 mg/4 weeks. UP: 45 mg/day 12 weeks, then 15 mg/day	13	15
13	F	CD	L3 + L4	-	No	No	5-ASA, GCS, AZA, MTX, INFL, ADA, golimumab, TAC, VD, TOF	VD + TOF/TOF + UST	VD: 10 mg/kg/6 weeks. TOF: 20 mg/day 8 weeks, then 5 mg/day. UST: 90 mg/8 weeks	2	11
14	F	CD	L3 + L4	-	No	No	5-ASA, GCS, INFL, AZA, TAC, SRL, VD	VD + TOF	VD: 10 mg/kg/6 weeks. TOF: 15 mg/day 8 weeks, then 10 mg/day	1	6
15	M	CD	L2	-	No	Yes	5-ASA, GCS, AZA, MTX, TAC, mycophenolate mofetil, INFL, ADA, UST	UST + UP	UST: 90 mg/4 weeks. UP: 45 mg/day 12 weeks, then 15 mg/day	5	17
16	M	CD	L3	-	No	No	5-ASA, GCS, AZA, MTX, TAC, INFL, ADA, VD	VD +UP	VD: 300 mg/4 weeks. UP: 45 mg/day 12 weeks, then 15 mg/day	5	12
17	F	CD	L2 + L4	-	Yes	No	GCS, AZA, MTX, INFL, ADA, UST	UST + UP	UST: 90 mg/8 weeks. UP: 45 mg/day 12 weeks, 15 mg/day	3	17
18	M	CD	L3	-	No	No	GCS, AZA, MTX, INFL, ADA, VD	VD + TOF	VD: 10 mg/kg/6 weeks. TOF: 10 mg/day	1	8

The first drug prescribed is underlined. ADA: Adalimumab; AZA: Azathioprine; CD: Crohn’s disease; F: Female; GCS: Glucocorticosteroids; INFL: Infliximab; M: Male; MTX: Methotrexate; SRL: Sirolimus; TAC: Tacrolimus; TOF: Tofacitinib; UC: Ulcerative colitis; UP: Upadacitinib; UST: Ustekinumab; VD: Vedolizumab; 5-ASA: 5-aminosalicylic acid.